CSIMarket
 
Eledon Pharmaceuticals Inc   (ELDN)
Other Ticker:  
 
 
Price: $1.6200 $0.08 5.195%
Day's High: $1.67 Week Perf: -0.61 %
Day's Low: $ 1.53 30 Day Perf: -11.48 %
Volume (M): 39 52 Wk High: $ 2.95
Volume (M$): $ 62 52 Wk Avg: $1.67
Open: $1.59 52 Wk Low: $1.07



 Market Capitalization (Millions $) 49
 Shares Outstanding (Millions) 30
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -89
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 0

Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of various diseases and disorders. The company is dedicated to improving patients' lives through the discovery, development, and commercialization of advanced pharmaceutical products.

Eledon Pharmaceuticals specializes in the research and development of therapeutics in areas such as oncology, neurology, immunology, and cardiovascular diseases. They aim to address unmet medical needs by developing drugs that target specific mechanisms or pathways responsible for these conditions.

The company's team of scientists, researchers, and medical professionals work towards identifying potential drug candidates and conducting extensive preclinical and clinical trials. They collaborate with academic institutions, research organizations, and industry partners to accelerate the development process and bring innovative treatments to patients.

Eledon Pharmaceuticals Inc. places a strong emphasis on cutting-edge technology, novel drug delivery systems, and personalized medicine. They believe in the power of precision medicine and aim to develop therapies that are tailored to individual patients, offering improved efficacy and safety profiles.

Overall, Eledon Pharmaceuticals Inc. is dedicated to advancing the field of biopharmaceuticals by bringing transformative therapies to market that have the potential to significantly impact patients' quality of life.


   Company Address: 19900 MacArthur Blvd Irvine 92612 CA
   Company Phone Number: 238-8090   Stock Exchange / Ticker: NASDAQ ELDN
   ELDN is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Eledon Pharmaceuticals Showcases Business Success, Solidifies Foothold Ahead of 2024: A Journey of Growth and Innovation.

Published Thu, Jan 4 2024 9:41 PM UTC

Eledon Pharmaceuticals Inc., since its inception, has consistently dedicated to leverage scientific discovery and drug development to address the world?s most pressing health-care challenges remarkably. The agenda is not only to innovate but also to ensure such path-breaking discoveries capably reach to those in need.During the corresponding period, the pharmaceutical giant ...

Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc Grapples with Soaring Working Outlays in Financial Third Quarter of 2023

Eledon Pharmaceuticals Inc, a renowned pharmaceutical company, recently released its financial results for the July to September 30, 2023 reporting cycle. While shareholders had hoped for some improvements in revenue, the company reported an operating loss of $-11.198 million during the same period. However, this can be seen as a smart policy decision given the current stage of the firm.
Comparing the operating loss of the third quarter of 2022, which was $-10.598 million, it is evident that there has been a slight increase in the operating loss. On a positive note, the company has managed to reduce the diminishing returns from $-10.471 million in the third quarter of 2022 to $-10.349 million in the same period of 2023. This reduction in diminishing returns may help the company emerge as a successful bellwether in the industry.

Eledon Pharmaceuticals Inc

Major Pharmaceutical Preparations Sector's Eledon Pharmaceuticals Inc. Presents More Sophisticated Fiscal Q2 2023 Earnings



In a surprising turn of events, Eledon Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, faces major financial challenges as the company reported an operating deficit of $-10.354 million during the April to June 2023 earnings season. This unexpected revelation has left shareholders concerned about the company's future prospects. In order to understand the current situation, it is important to analyze Eledon Pharmaceuticals' performance in recent years, particularly during the second quarter of 2022 when the company recorded an operating deficit of $-9.283 million.
Operating Deficit Persists:
Eledon Pharmaceuticals Inc. has experienced a persistently large operating deficit in recent years, indicating potential challenges in its business strategy. This deficit expanded even further in the most recent fiscal period, reaching $-9.579 million. The discrepancies between shareholder expectations and actual financial results suggest a need for Eledon Pharmaceuticals to revisit and revise its approach to maintaining a profitable position.

Eledon Pharmaceuticals Inc

Headline: Eledon Pharmaceuticals Inc Faces Decline in Company Conduct from January to March 31, 2023 Period## Smaller Pharmaceutical Company Eledon Pharmaceuticals Inc Struggles to Generate Revenue Despite Narrowing Financial Shortfall

In the pharmaceutical industry, it's common to hear about the large corporations who dominate the market and create blockbuster drugs that earn billions of dollars in revenue. But what about the smaller companies? How are they faring in this highly competitive industry?
One such company, Eledon Pharmaceuticals Inc, has recently published its financial numbers for the first quarter of 2023. The company reported an operating shortfall of $-11.11 million, which is an improvement from the $-9.859 million shortfall from the previous year. However, the real question on everyone's mind is whether Eledon Pharmaceuticals Inc will start to generate revenue soon.
The company's management is reportedly exploring different strategies to ensure a successful product line, as the shortfall persists. There's no doubt that this is a crucial time for the company, as it seeks to make a name for itself in the pharmaceutical industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com